



I. Epidemiological profile

Population (UN Population Division)	2012	%
High transmission (>1 case per 1000 population)	1 350 000	5
Low transmission (0–1 cases per 1000 population)	3 450 000	12
Malaria-free (0 cases)	25 200 000	84
Total	30 000 000	



Parasites and vectors	
Major plasmodium species:	<i>P. falciparum</i> (11%), <i>P. vivax</i> (89%)
Major anopheles species:	<i>An. darlingi</i> , <i>pseudopunctipennis</i> , <i>albimanus</i>
Programme phase: Control	

II. Intervention policies and strategies



Intervention	Policies/strategies	Yes/No	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	–
	ITNs/LLINs distributed to all age groups	Yes	–
IRS	IRS is recommended	Yes	–
	DDT is used for IRS	No	–
Larval control	Use of larval control	No	–
IPT	IPT used to prevent malaria during pregnancy	N/A	–
Diagnosis	Patients of all ages should receive diagnostic test	Yes	–
	Malaria diagnosis is free of charge in the public sector	Yes	–
Treatment	ACT is free for all ages in public sector	Yes	–
	Artemisinin-based monotherapies withdrawn	Yes	–
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for <i>P. falciparum</i>	Yes	–
	Primaquine is used for radical treatment of <i>P. vivax</i>	No	–
	G6PD test is a requirement before treatment with primaquine	No	–
	Directly observed treatment with primaquine is undertaken	Yes	–
	System for monitoring of adverse reaction to antimalarials exists	Yes	–

Intervention	Policies/strategies	Yes/No	Year adopted				
Surveillance	ACD for case investigation (reactive)	Yes	–				
	ACD at community level of febrile cases (pro-active)	Yes	–				
	Mass screening is undertaken	Yes	–				
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	–				
	Uncomplicated <i>P. vivax</i> cases routinely admitted	Yes	–				
Antimalaria treatment policy			Year adopted				
First-line treatment of unconfirmed malaria		–	–				
First-line treatment of <i>P. falciparum</i>		AS+MQ	–				
For treatment failure of <i>P. falciparum</i>		–	–				
Treatment of severe malaria		–	–				
Treatment of <i>P. vivax</i>		CQ+PQ	–				
Dosage of primaquine for radical treatment of <i>P. vivax</i>		–	–				
Type of RDT used		–	–				
Therapeutic efficacy tests (clinical and parasitological failure, %)							
Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
AS+MQ	2005–2006	1.1	1.1	1.1	28 days	1	<i>P. f</i>





III. Financing



IV. Coverage



V. Impact



Impact: On track for >75% decrease in incidence 2000–2015